- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Developing Pharma-Grade Medical Cannabis in Europe
Overview
Pharmadrug Inc. (CSE:BUZZ,OTC:LMLLF) is a German medical cannabis distributor with an 80 percent ownership in Pharmadrug Production GmbH, a Schedule I European Union narcotics license holder with the ability to import and distribute medical cannabis in Germany and throughout the EU. In addition, the company owns a convertible note into 54 percent equity of HolyCanna Ltd., a cultivation and nursery license holder in Israel, and has a binding LOI to purchase 57 percent of CannabiSendak Ltd., the builder of a network of dispensaries in Israel.
Pharmadrug Company Highlights
- Pharmadrug is a pure-play on the European cannabis market, which is expected to be the biggest consumer of cannabis in the world with more than 740 million people.
- The company owns 80 percent of Pharmadrug, one of 15 holders of a Class I narcotics license to import and distribute medical cannabis in Germany and anywhere in EU.
- Strategic investments in Israel from seed-to-sale.
- Upside in the high margin, downstream extraction space.
This article was written according to INN editorial standards to educate investors. INN does not guarantee the accuracy or thoroughness of the information contained on this page.
INN does not provide investment advice and the information on Investingnews.com profile should not be considered a recommendation to buy or sell any security.
INN does not endorse or recommend the business, products, services or securities of any company profiled.
Readers should conduct their own research for all information publicly available concerning the company.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â